Nicole Faust, Ph.D., CEO

Cologne, Germany


Virtual Presentation

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vector vaccines and complex recombinant proteins. With the ELEVECTA® Technology, CEVEC offers a unique solution for large scale production of AAV vectors using producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any transfection reagents, cGMP plasmids, or helper virus. CEVEC’s CAP® Technology, based on human suspension cells, is the ideal production platform for RCA-free adenoviral vectors, lentiviral vectors, oncolytic viruses, viral vaccines, and exosomes.


By using this website you agree to accept our Privacy Policy and Terms & Conditions